Catalent Expands Packaging Capabilities in Singapore

Article

Applied Clinical Trials

Catalent Singapore facility is awarded GMP certification.

Catalent, a global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, announced that it has expanded its Singapore facility, which recently received GMP approval from the Health Science Authority, to provide secondary packaging and labeling capabilities. The site is now fully approved for GMP across all its activities, including secondary packaging, label printing, storage, distribution, returns and destruction management.   Read the full release here.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Recent Videos
Related Content
© 2025 MJH Life Sciences

All rights reserved.